SCHEMBL3344656

SCHEMBL3344656

COC(=O)Cc1cc(C)cc2[nH]c(=O)c(Cc3ccc(Cl)cc3)c(C)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.41
KDM4E B2RXH2 6/20 0.39
ALDH1A1 P00352 5/20 0.39
HPGD P15428 2/20 0.39
ALOX15 P16050 2/20 0.39
MAPK1 P28482 2/20 0.39
USP2 O75604 1/20 0.39
ALOX12 P18054 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CNR1 P21554 1/20 0.39
HSD17B10 Q99714 2/20 0.39
GAA P10253 2/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3344758 0.88 PTGDR2 (0.51) TP53KDM4EALDH1A1HPGDALOX15
SCHEMBL3349053 0.81 ALDH1A1 (0.45) KDM4EALDH1A1HPGDALOX15MAPK1
SCHEMBL5328927 0.80 PTGDR2 (0.64) TP53KDM4EALDH1A1HPGDMAPK1
SCHEMBL3346140 0.79 PTGDR2 (0.38) TP53KDM4EALDH1A1HPGDALOX15
SCHEMBL3345079 0.79 ALDH1A1 (0.42) TP53KDM4EALDH1A1HPGDHSD17B10
SCHEMBL3775770 0.79 PLA2G2A (0.45) TP53KDM4EALDH1A1HPGDALOX15
SCHEMBL3345539 0.78 ALDH1A1 (0.46) TP53KDM4EALDH1A1HPGDALOX15
SCHEMBL3348700 0.78 ALDH1A1 (0.41) TP53KDM4EALDH1A1HPGDCNR1
SCHEMBL3344676 0.78 TDP1 (0.44) TP53KDM4EALDH1A1HPGDUSP2
SCHEMBL3345040 0.78 PTGDR2 (0.39) TP53KDM4EALDH1A1ALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
WO-2010040989-A1 QUINOLIN-2-ONE COMPOUNDS ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-04-15 WO disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 TP53 4092/4885KDM4E 4638/4885ALDH1A1 4201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.